Compare IQV & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IQV | TEVA |
|---|---|---|
| Founded | 1982 | 1901 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.4B | 30.2B |
| IPO Year | 2013 | N/A |
| Metric | IQV | TEVA |
|---|---|---|
| Price | $230.79 | $26.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 7 |
| Target Price | ★ $236.71 | $25.86 |
| AVG Volume (30 Days) | 1.4M | ★ 14.4M |
| Earning Date | 10-28-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.30 | 0.62 |
| Revenue | $15,904,000,000.00 | ★ $16,776,000,000.00 |
| Revenue This Year | $6.14 | $4.11 |
| Revenue Next Year | $5.28 | $0.40 |
| P/E Ratio | ★ $31.49 | $42.65 |
| Revenue Growth | ★ 3.85 | 0.02 |
| 52 Week Low | $134.65 | $12.47 |
| 52 Week High | $234.30 | $26.96 |
| Indicator | IQV | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 68.05 | 75.91 |
| Support Level | $228.69 | $24.01 |
| Resistance Level | $234.30 | $26.38 |
| Average True Range (ATR) | 5.76 | 0.74 |
| MACD | 0.89 | 0.05 |
| Stochastic Oscillator | 83.07 | 94.80 |
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.